Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma
Andrew M. Evens, DO, MSc, on the early results of ECOG-ACRIN E2408 trial, which found that adding bortezomib to standard bendamustine-rituximab treatment increases the number of complete remissions in patients with high-risk lymphoma.
Novartis and the Bill and Melinda Gates Foundation are collaborating on a one-step, one-time gene therapy for patients with sickle cell disease (SCD). The...
The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for zanubrutinib for the treatment of adult patients with...
The combination of daratumumab and hyaluronidase-fihj and bortezomib, cyclophosphamide, and dexamethasone (D-VCd) was granted accelerated approval for the treatment of adults with newly diagnosed...